Use of retroviral-mediated gene transfer to deliver and test function of chimeric antigen receptors in human T-cells
Chimeric antigen receptors (CARs) are genetically delivered fusion molecules that elicit T-cell activation upon binding of a native cell surface molecule. These molecules can be used to generate a large number of memory and effector T-cells that are capable of recognizing and attacking tumor cells. Most commonly, stable CAR expression is achieved in T-cells using retroviral vectors. In the method described here, retroviral vectors are packaged in a two-step procedure. First, H29D human retroviral packaging cells (a derivative of 293 cells) are transfected with the vector of interest, which is packaged transiently in vesicular stomatitis virus (VSV) G pseudotyped particles. These particles are used to deliver the vector to PG13 cells, which achieve stable packaging of gibbon ape leukaemia virus (GALV)-pseudotyped particles that are suitable for infection of human T-cells. The key advantage of the method reported here is that it robustly generates polyclonal PG13 cells that are 100% positive for the vector of interest. This means that efficient gene transfer may be repeatedly achieved without the need to clone individual PG13 cells for experimental pre-clinical testing. To achieve T-cell transduction, cells must first be activated using a non-specific mitogen. Phytohemagglutinin (PHA) provides an economic and robust stimulus to achieve this. After 48-72 h, activated T-cells and virus-conditioned medium are mixed in RetroNectin-coated plasticware, which enhances transduction efficiency. Transduced cells are analyzed for gene transfer efficiency by flow cytometry 48 h following transduction and may then be tested in several assays to evaluate CAR function, including target-dependent cytotoxicity, cytokine production and proliferation.
1. Maher J (2012) Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012: 278093.
2. Maher J (2014) Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells. Curr Gene Ther 14: 35-43.
3. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, et al. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
4. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, et al. (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118: 6050-6056.
5. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
6. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, et al. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
7. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra138.
8. Wilkie S, Picco G, Foster J, Davies DM, Julien S, et al. (2008) Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 180: 4901-4909.
9. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, et al. (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64: 9160-9166.
10. Shaffer DR, Savoldo B, Yi Z, Chow KK, Kakarla S, et al. (2011) T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 117: 4304-4314.
11. Davies DM, Foster J, Van Der Stegen SJ, Parente-Pereira AC, Chiapero-Stanke L, et al. (2012) Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med 18: 565-576.
12. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, et al. (2012) Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4: 132ra153.
13. Ory DS, Neugeboren BA, Mulligan RC (1996) A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A 93: 11400-11406.
14. Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, et al. (1991) Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 65: 2220-2224.
15. Gallardo HF, Tan C, Ory D, Sadelain M (1997) Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90: 952-957.
16. Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, et al. (2013) Clinical application of sleeping beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp (72): 50070.
17. Riviere I, Gallardo HF, Hagani AB, Sadelain M (2000) Retroviral-mediated gene transfer in primary murine and human T-lymphocytes. Mol Biotechnol 15: 133-142.
18. Zhong S, Malecek K, Perez-Garcia A, Krogsgaard M (2010) Retroviral transduction of T-cell receptors in mouse T-cells. J Vis Exp (44).
19. Kerkar SP, Sanchez-Perez L, Yang S, Borman ZA, Muranski P, et al. (2011) Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J Immunother 34: 343-352.
20. Riviere I, Brose K, Mulligan RC (1995) Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A 92: 6733-6737.
21. Schuberth PC, Jakka G, Jensen SM, Wadle A, Gautschi F, et al. (2013) Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther 20: 386-395.
22. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 20: 70-75.
23. Maher J, Wilkie S (2009) CAR mechanics: driving T cells into the MUC of cancer. Cancer Res 69: 4559-4562.
24. Wilkie S, Burbridge SE, Chiapero-Stanke L, Pereira AC, Cleary S, et al. (2010) Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem 285: 25538-25544.